View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 4, 2021updated 14 Feb 2022 10:18am

Medtronic to discontinue supply and marketing of HVAD

This development comes after the company received nearly 100 complaints on the delay or failure to restart the HVAD pump.

Medtronic has announced that the company is discontinuing the supply and marketing of its HeartWare ventricular assist device (HVAD) due to a high incidence of neurological adverse events.

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

The HVAD system is indicated for hemodynamic support in advanced, refractory left ventricular heart failure patients. It is used either as a bridge to cardiac transplantation, myocardial recovery or as destination treatment in those patients with no transplantation planned.

Medtronic’s decision follows more than 100 complaints that the company received on the delay or failure to restart the HVAD pump. These complaints include 14 deaths and 13 cases of explant.

The company is currently creating a support programme for patients with an HVAD implant as well as for the care providers and healthcare experts involved in their care.

An independent team of clinician advisors is developing the programme with a focus on the ongoing care and safety of patients with the HVAD system.

The company also alerted doctors to stop new implants of the system and shift to an alternate option of durable mechanical circulatory support.

There are nearly 2,000 patients in the US who are implanted with the HVAD and 4,000 globally, Medtronic noted.

The plan to discontinue the HVAD system is based on observational clinical comparisons showing an increased incidence of neurological adverse events, such as stroke, as well as mortality with the device, versus other available circulatory support devices.

Medtronic mechanical circulatory support business president Nnamdi Njoku said: “There is nothing more important than the safety and well-being of patients.

“We recognise this information may be concerning for patients and their caregivers, and Medtronic is committed to supporting them in coordination with their physicians.”

Meanwhile, Abbott said that the company is equipped with the capacity and supply to support the increasing need for mechanical circulatory support devices for the treatment of advanced heart failure.

This announcement follows Medtronic’s decision to stop the sale of HVAD.

Last month, Medtronic received CE mark for its Evolut PRO+ TAVI System in Europe to treat patients with symptomatic severe aortic stenosis.

Related Companies

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network